Top Pharma news of the day

Sun Pharmaceutical's $3.2-billion acquisition of Ranbaxy Laboratories, which has made it the nation's largest drug maker, has opened an exit door for many employees and a hiring ground for rivals.

Sun Pharmaceutical's $3.2-billion acquisition of Ranbaxy Laboratories, which has made it the nation's largest drug maker, has opened an exit door for many employees and a hiring ground for rivals.

Cipla has its skin in the game, quite literally. The country's third-largest drug maker has acquired the exclusive rights to market skin care products of the country's leading derma and cosmeceutical player Percos India, in a deal worth an estimated Rs 90 crore.

The founder and CEO of India's second largest retail pharmacy chain MedPlus Health Services Madhukar Gangadi along with a clutch of private equity investors in the company have put it up for sale. 

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 892.6, up by 2.45 points or 0.28% from its previous closing of Rs. 890.15 on the BSE.

The scrip opened at Rs. 898 and has touched a high and low of Rs. 901.9 and Rs. 890.9 respectively. So far 671871 shares were traded on the counter. The current market cap of the company is Rs. 214214.25 crore.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1200.8 on 07-Apr-2015 and a 52 week low of Rs. 748 on 26-Sep-2014. Last one week high and low of the scrip stood at Rs. 917 and Rs. 865 respectively.

The promoters holding in the company stood at 54.71 % while Institutions and Non-Institutions held 31.51 % and 13.78 % respectively.

The stock is currently trading below its 200 DMA.